immunocompromised patients – Page 10

Incidence And Risk Factors for Invasive Fungal Infections in Pre-Transplant and Transplant-Ineligible Multiple Myeloma in the U.S.: A Claims Analysis (2017-2021)

mycolabadmin

This study examined fungal infections in patients with multiple myeloma who were not eligible for or preparing for stem cell transplants. Researchers found that 6% of these patients developed invasive fungal infections, with yeast infections being the most common type. The risk of these infections was significantly higher in patients taking dexamethasone (a steroid) or those with low white blood cell counts and those receiving multiple cancer therapies.

Recognizing the Importance of Public Health Mycology

mycolabadmin

This editorial highlights how fungal infections are a growing but overlooked global health crisis, killing about 2.5 million people annually. The paper brings together seven research articles studying different fungal diseases, from lung infections to skin conditions, showing how these diseases spread differently in different populations and how resistance to antifungal medications is increasing. The authors emphasize that better testing, treatment access, and worldwide disease tracking are urgently needed, especially in poorer countries where the burden of fungal disease is highest.

Antifungal Activity of Selected Naphthoquinones and Their Synergistic Combination with Amphotericin B Against Cryptococcus neoformans H99

mycolabadmin

Scientists tested five synthetic compounds called naphthoquinones to see if they could fight a serious fungal infection called cryptococcosis. They found that one compound called 2-MNQ worked well against the fungus and was even more effective when combined with a standard antifungal drug (amphotericin B). The combination was strong enough to potentially allow lower doses of the existing drug, which could reduce side effects while improving treatment outcomes.

Cryptococcus albidus (Naganishia albida) meningitis in a young patient with T-cell acute lymphoblastic leukaemia

mycolabadmin

A 16-year-old boy with blood cancer (T-ALL) developed a brain infection caused by a rare fungus called Cryptococcus albidus. Doctors initially thought he had a viral infection caused by herpes, but tests on his spinal fluid revealed the true fungal culprit. He was treated with antifungal medications that led to his recovery, emphasizing the importance of thorough testing when immunocompromised patients develop serious infections.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections in people with weakened immune systems. This study reviewed and analyzed three clinical trials to compare how well isavuconazole works compared to other antifungal drugs. The results showed that isavuconazole is just as effective as other antifungals but has fewer side effects, particularly fewer problems with liver health and drug-related adverse events. This makes isavuconazole a good alternative choice for patients who cannot use other antifungal medications or who are at risk of liver damage.

Pan-Indian Clinical Registry of Invasive Fungal Infections Among Patients in the Intensive Care Unit: Protocol for a Multicentric Prospective Study

mycolabadmin

Fungal infections are a serious hidden threat in hospital intensive care units, particularly for patients with weakened immune systems. This study establishes India’s first comprehensive database system to track fungal infections across 8 major medical centers nationwide. By collecting detailed information about these infections and how they respond to treatments, the research aims to help doctors diagnose and treat fungal infections faster and more effectively. The findings will guide better clinical practices and public health policies to combat these often-neglected but deadly infections.

Geotrichosis Due to Magnusiomyces capitatus: A Severe Emerging Invasive Fungal Disease

mycolabadmin

A 71-year-old cancer patient receiving chemotherapy developed a severe blood infection caused by a rare fungus called Magnusiomyces capitatus. This emerging fungal infection caused septic shock and multiple organ failure despite treatment with antifungal medications. The case highlights how these rare fungi can be deadly in patients with weakened immune systems and emphasizes the importance of quick, accurate identification using advanced laboratory techniques to guide treatment decisions.

The Brief Case: Cutaneous ulceration associated with acalabrutinib treatment

mycolabadmin

A 72-year-old patient being treated with acalabrutinib for blood cancer developed a slowly growing skin ulcer on the thigh. Testing identified a fungal infection caused by Alternaria alternata, a mold found in soil and air. The patient was successfully treated with an antifungal medication called posaconazole, with the ulcer healing over one month. This case highlights that doctors should check for fungal infections in chronic skin wounds of patients taking BTK inhibitor medications.

Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics

mycolabadmin

This editorial discusses the growing challenge of fungal infections worldwide, which disproportionately affect people with weakened immune systems. New diagnostic tools using molecular testing can now quickly identify fungal infections, while researchers are developing novel treatments including repurposed drugs and immune-boosting therapies. The article emphasizes that coordinated efforts among doctors, scientists, and public health officials are essential to combat rising antifungal resistance and improve patient outcomes.

Research Keyword: immunocompromised patients